Molecular Express, Inc
Dba Molecular Express Inc
CAGE Code: 337D8
NCAGE Code: 337D8
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 058878682
Summary
Molecular Express, Inc, Dba Molecular Express Inc is an Active Commercial Supplier with the Cage Code 337D8 and is tracked by Dun & Bradstreet under DUNS Number 058878682..
Address
2630 Homestead Pl
Rancho Dominguez CA 90220-5610
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Sea Recovery Corporation A. Lowy Enterprises, Inc. Biocell Laboratories, Inc. Pioneer Power Systems, Inc. K T Engineering Corp Southland Laundry Systems Fairway Import-Export, Inc. Mover Services, Inc. Contact Office Solutions, Inc Calpipe Industries, Inc. Schwarzkopf & Dep, Inc. Cj Logistics Holdings America Corp Spectrum Lifesciences, Llc Molecular Gps Enterprises Crossfield Products Corp. Playfield Turf Llc Ctsi Logistics Inc Selectron, Inc. Community Family Educational Dsa/Phototech, Llc
Frequently Asked Questions (FAQ) for CAGE 337D8
- What is CAGE Code 337D8?
- 337D8 is the unique identifier used by NATO Organizations to reference the physical entity known as Molecular Express, Inc Dba Molecular Express Inc located at 2630 Homestead Pl, Rancho Dominguez CA 90220-5610, United States.
- Who is CAGE Code 337D8?
- 337D8 refers to Molecular Express, Inc Dba Molecular Express Inc located at 2630 Homestead Pl, Rancho Dominguez CA 90220-5610, United States.
- Where is CAGE Code 337D8 Located?
- CAGE Code 337D8 is located in Rancho Dominguez, CA, USA.
Contracting History for CAGE 337D8 Most Recent 25 Records
- 75N93023C00033
- Development Of Vesivax Co-Adjuvant Formulation Of 2E151.
- 29 Aug 2023
- Development Of Vesivax Co-Adjuvant Formulation Of 2E151.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,925.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00012
- Vesivax Hivgp41e Vaccine Design
- 19 May 2023
- Vesivax Hivgp41e Vaccine Design
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $300,000.00
- Department Of Health And Human Services (Hhs)
- 75N93022C00012
- The Contractor Shall To Engineer Novel Hiv Gp41 Ectodomain Antigens (Hiv Gp41e-Hd) For The Incorporation Into The Immunogenic Vesivax Formulations.
- 23 Jun 2022
- The Contractor Shall To Engineer Novel Hiv Gp41 Ectodomain Antigens (Hiv Gp41e-Hd) For The Incorporation Into The Immunogenic Vesivax Formulations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $300,000.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00027
- The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- 9 May 2022
- The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,994.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00039
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- 29 Sep 2021
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $569,807.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00039
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- 30 Nov 2021
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $569,807.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00027
- The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- 28 Jun 2021
- The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,994.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00039
- Eo14042 - Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- 15 Oct 2021
- Eo14042 - Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $569,807.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00039
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- 25 Feb 2022
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $569,807.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00039
- Development Of A Vesivas Immunosimilar Formulation
- 21 Jul 2021
- Development Of A Vesivas Immunosimilar Formulation
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $569,807.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00039
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- 25 Feb 2022
- Development Of A Vesivas Immunosimilar Formulation Edited By Lnguyen_Nih On 09/29/2021 15:54:41 Edited By Lnguyen_Nih On 09/29/2021 15:54:52
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $569,807.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00027
- The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- 23 Jun 2022
- The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,294,565.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00027
- Eo14042 - The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- 15 Oct 2021
- Eo14042 - The Contractor Shall To Evaluate The Different Co-Delivery Methods Of A Model Hiv Antigen Using The Vesivax Liposomal Platform.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,994.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00010
- Eo14042: The Objective Of This Contract Is To Identify A Potential Hiv Antigen-Conjugated Vaccine Formulation By Exploring Co-Delivery Of Hiv Antigens And Adjuvant Molecules.
- 29 Nov 2021
- Eo14042: The Objective Of This Contract Is To Identify A Potential Hiv Antigen-Conjugated Vaccine Formulation By Exploring Co-Delivery Of Hiv Antigens And Adjuvant Molecules.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,961.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00012
- The Objective Of This Contract Is To Develop A Vesivax Platform-Based Liposomal Formulation That Will Efficiently Display The Hiv Immunogen.
- 22 Sep 2022
- The Objective Of This Contract Is To Develop A Vesivax Platform-Based Liposomal Formulation That Will Efficiently Display The Hiv Immunogen.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,993.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00012
- Eo14042: The Objective Of This Contract Is To Develop A Vesivax Platform-Based Liposomal Formulation That Will Efficiently Display The Hiv Immunogen.
- 29 Nov 2021
- Eo14042: The Objective Of This Contract Is To Develop A Vesivax Platform-Based Liposomal Formulation That Will Efficiently Display The Hiv Immunogen.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,993.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00012
- The Objective Of This Contract Is To Develop A Vesivax Platform-Based Liposomal Formulation That Will Efficiently Display The Hiv Immunogen.
- 6 May 2022
- The Objective Of This Contract Is To Develop A Vesivax Platform-Based Liposomal Formulation That Will Efficiently Display The Hiv Immunogen.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $299,993.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00007
- The Objective Of This Contract Is To Develop An Effective Hiv Vaccine By Exploring Co-Delivery Formulations Of Hivantigens And Adjuvants.
- 30 May 2019
- The Objective Of This Contract Is To Develop An Effective Hiv Vaccine By Exploring Co-Delivery Formulations Of Hivantigens And Adjuvants.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $599,983.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00053
- De-Obligate Fy-18 Funds In The Amount Of $19,864.00
- 30 Jun 2023
- De-Obligate Fy-18 Funds In The Amount Of $19,864.00
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $193,936.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00053
- Completion Date: January 31, 2020 (Unchanged) Total Contract Amount Of $213,800 Is Changed By $19,864 To $193,938 Total Obligated Amount Of $213,800 Is Changed By $19,864 To $193,938
- 24 Sep 2018
- Completion Date: January 31, 2020 (Unchanged) Total Contract Amount Of $213,800 Is Changed By $19,864 To $193,938 Total Obligated Amount Of $213,800 Is Changed By $19,864 To $193,938
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $213,800.00
- Department Of Health And Human Services (Hhs)